This profile is for informational purposes only and is not medical advice. Consult a healthcare professional before use. See full terms.
Memantine
An NMDA receptor antagonist approved for Alzheimer's disease treatment - used off-label at low doses for neuroprotection, glutamate regulation, and reducing excitotoxicity-related cognitive decline.
Benefits
What is Memantine?
Memantine is an uncompetitive, voltage-dependent NMDA receptor antagonist approved by the FDA in 2003 for moderate-to-severe Alzheimer's disease under the brand name Namenda. It represents a fundamentally different approach to neuroprotection compared to cholinesterase inhibitors - rather than boosting a depleted neurotransmitter, it protects neurons from the damaging effects of excessive glutamate signalling.
Glutamate is the brain's primary excitatory neurotransmitter, essential for learning and memory. However, chronic low-level overactivation of NMDA receptors by glutamate - a phenomenon called excitotoxicity - is a major driver of neuronal damage in Alzheimer's, other neurodegenerative diseases, and normal ageing. Memantine sits in the NMDA receptor channel and blocks this pathological tonic activation while still allowing the brief, strong glutamate signals needed for normal learning and memory (LTP). A 2005 meta-analysis published in Dementia and Geriatric Cognitive Disorders covering 6 large randomised controlled trials confirmed that memantine significantly improved cognition, activities of daily living, and global function in Alzheimer's patients. At lower doses, memantine is used off-label in the nootropics community for neuroprotection, with reports of improved mental clarity and reduced brain fog. A 2016 study in Neuropharmacology showed that memantine enhanced BDNF signalling and promoted synaptic plasticity at therapeutic doses, suggesting benefits beyond simple neuroprotection.
- NMDA receptor channel block: Sits in the NMDA receptor ion channel with moderate affinity, blocking pathological tonic glutamate activation (excitotoxicity) while allowing normal phasic signalling for learning and memory
- Voltage dependence: The block is voltage-dependent - memantine is expelled from the channel during strong depolarisation events (normal synaptic transmission), allowing LTP to proceed normally
- Magnesium-like mechanism: Mimics and enhances the physiological voltage-dependent Mg2+ block of NMDA receptors that is impaired in ageing and disease
- BDNF enhancement: Promotes BDNF expression and signalling, supporting neuroplasticity and synaptic maintenance
- 5-HT3 antagonism: Blocks serotonin 5-HT3 receptors, which may contribute to anti-nausea effects and mood regulation
- Sigma-1 receptor agonism: Activates sigma-1 receptors, supporting calcium homeostasis and endoplasmic reticulum stress responses in neurons
- Clinical Alzheimer's dosage: 20 mg per day (titrated from 5 mg over 4 weeks), prescription only
- Off-label nootropic dosage: 5-10 mg per day, often started at 2.5-5 mg to assess individual response
- Titration important: Start at the lowest dose and increase gradually over 1-2 weeks. Rapid dose escalation may cause dizziness or confusion
- Half-life: 60-80 hours, allowing once-daily dosing. Steady state reached after approximately 2 weeks
- Timing: Take at the same time each day, with or without food. Evening dosing may cause insomnia in some individuals
- Prescription medication: Memantine is a prescription drug in all major markets. Off-label nootropic use should ideally be discussed with a physician
- Common side effects: Dizziness, headache, confusion, and constipation are the most frequently reported. Generally mild and transient
- Dissociative effects: At higher doses or in sensitive individuals, NMDA antagonism may cause mild dissociative-like effects, derealization, or cognitive dulling
- Renal excretion: Primarily excreted by the kidneys. Dose reduction required in individuals with impaired kidney function
- Drug interactions: Avoid combining with other NMDA antagonists (ketamine, dextromethorphan). May interact with amantadine, carbonic anhydrase inhibitors, and drugs that alkalinise urine
Natural Sources & Forms
- Prescription (Namenda): 5 mg and 10 mg tablets, and extended-release 7 mg, 14 mg, 21 mg, 28 mg capsules
- Generic memantine: Widely available as generic memantine hydrochloride tablets, significantly cheaper than brand name
- Oral solution: 2 mg/mL oral solution available for precise low-dose titration
Frequently Asked Questions
An NMDA receptor antagonist approved for Alzheimer's disease treatment - used off-label at low doses for neuroprotection, glutamate regulation, and reducing excitotoxicity-related cognitive decline.
The key benefits of Memantine include: Anxiety & Calm, Cognitive Enhancement, Focus, Longevity, Memory, Mood.
NMDA receptor channel block: Sits in the NMDA receptor ion channel with moderate affinity, blocking pathological tonic glutamate activation (excitotoxicity) while allowing normal phasic signalling for learning and memory Voltage dependence: The block is voltage-dependent - memantine is expelled from the channel during strong depolarisation events (normal synaptic transmission), allowing LTP to proceed normally Magnesium-like mechanism: Mimics and enhances the physiological voltage-dependent Mg2+ block of NMDA receptors that is impaired in ageing and disease BDNF enhancement: Promotes BDNF expression and signalling, supporting neuroplasticity and synaptic maintenance 5-HT3 antagonism: Blocks serotonin 5-HT3 receptors, which may contribute to anti-nausea effects and mood regulation Sigma-1 receptor agonism: Activates sigma-1 receptors, supporting calcium homeostasis and endoplasmic reticulum stress responses in neurons
Clinical Alzheimer's dosage: 20 mg per day (titrated from 5 mg over 4 weeks), prescription only Off-label nootropic dosage: 5-10 mg per day, often started at 2.5-5 mg to assess individual response Titration important: Start at the lowest dose and increase gradually over 1-2 weeks. Rapid dose escalation may cause dizziness or confusion Half-life: 60-80 hours, allowing once-daily dosing. Steady state reached after approximately 2 weeks Timing: Take at the same time each day, with or without food. Evening dosing may cause insomnia in some individuals
Prescription medication: Memantine is a prescription drug in all major markets. Off-label nootropic use should ideally be discussed with a physician Common side effects: Dizziness, headache, confusion, and constipation are the most frequently reported. Generally mild and transient Dissociative effects: At higher doses or in sensitive individuals, NMDA antagonism may cause mild dissociative-like effects, derealization, or cognitive dulling Renal excretion: Primarily excreted by the kidneys. Dose reduction required in individuals with impaired kidney function Drug interactions: Avoid combining with other NMDA antagonists (ketamine, dextromethorphan). May interact with amantadine, carbonic anhydrase inhibitors, and drugs that alkalinise urine
Overall Rating
Log in to rate this nootropic.
Comments
Log in to leave a comment.
No comments yet. Be the first to share your experience!